Replimune Group announced a proposed public offering of $125M of shares of its common stock and pre-funded warrants to purchase shares of common stock. J.P. Morgan Securities and SVB Securities are acting as joint book-running managers for the proposed offering.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on REPL:
- Replimune Announces Proposed Public Offering
- Replimune Group announces updates on RP2/3 data, development plans
- Replimune Group announces initial data from IGNYTE trial on RP1
- Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update
- Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma